PHARMACEUTICAL TECHNOLOGY OF PHARMACEUTICAL COMPOSITION IN NOVEL/SEQUENTIAL DRUG DELIVERY SYSTEM CONTAINING NITRIC OXIDE DONORS, MORE PARTICULARLY, SELECTIVE ENDOTHELIAL NITRIC OXIDE SYNTHASE ENHANCERS AND IN SYNERGISTIC COMBINATION WITH NITIC OXIDE SCAVENGERS LIPID LOWERING AGENTS, AS NANONISED PARTICLES, FROM AMONGST, HMG CO-A REDUCTASE INHIBITORS, EZETIMIBE, FIBRATES AND ADDITIONALLY OTHER PHARMACEUTICAL SUBSTANCES THATATHEROSCLEROSIS AND PROVIDE ROUND-THE-CLOCK CARDIOPROTECTION

摘要

The present invention relates to pharmaceutical technology of pharmaceutical composition in Novel/Sequential Drug Delivery System containing Nitric Oxide Donors, more particularly, selective Endothelial Nitric Oxide Synthase Enhancers and in synergistic combination with Nitic Oxide Scavengers, Lipid Lowering Agents, as nanonised particles, from amongst, HMG Co-A Reductase Inhibitors, Ezetimibe and Fibrates and additionally other pharmaceutical substances that prevent/treat Atherosclerosis and provide round-the-clock cardio-protection. Following are the specific objectives of the present invention: a) Provide optimum benefits of Nitric Oxide and make it devoid of its adverse effects, through our unique technology and thus make it relatively safe for long-term usage. b) Provide synergistic combination of Lipid Lowering Agents with Nitric Oxide to achieve the dual objectives of a) Vasodilatation and b) Improve Dyslipidemia. c) Improve Quality of Life in patients with Ischemic Heart Disease.